Literature DB >> 20940369

Effects of chronic kidney disease and post-angiographic acute kidney injury on long-term prognosis after coronary artery angiography.

Tomonori Kimura1, Yoshitsugu Obi, Keiko Yasuda, Ko-ichi Sasaki, Yoshihiro Takeda, Yoshiyuki Nagai, Enyu Imai, Hiromi Rakugi, Yoshitaka Isaka, Terumasa Hayashi.   

Abstract

BACKGROUND: Both chronic kidney disease (CKD) and post-angiographic acute kidney injury (AKI) are regarded as risks factors for long-term mortality after coronary angiography. On the other hand, acute haemodynamic disturbances requiring haemodynamic support have a strong impact on both the incidence of AKI and on prognosis after coronary angiography. The aim of this study was to determine the impact of CKD and AKI on long-term prognosis after coronary angiography among hospital survivors and to determine relationships with haemodynamic variables.
METHODS: We studied 2439 patients who underwent coronary angiography or percutaneous coronary intervention. Relationships between both CKD and AKI and mortality or cardiovascular diseases were measured using unadjusted and adjusted Cox models for case-mix and laboratory variables.
RESULTS: Multivariable Cox regression analysis identified CKD as an independent predictor of long-term mortality [adjusted hazard ratio (AHR) 1.51; 95% confidence interval (95% CI) 1.07-2.13] and composite end points (AHR 1.72; 95% CI 1.40-2.11). Lower estimated glomerular filtration ratio levels below 50 mL/min/1.73 m(2) were significantly associated with mortality after adjustments. A similar association was found even in haemodynamically stable patients. AKI was also a predictor of long-term composite end points (AHR 1.64; 95% CI 1.09-2.46); however, its impact was attenuated in haemodynamically stable patients.
CONCLUSIONS: Among hospital survivors, CKD is an independent predictor for both long-term mortality and composite end points, regardless of haemodynamic conditions. AKI is also a predictor of long-term prognosis; however, its impact may be attenuated in haemodynamically stable hospital survivors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20940369     DOI: 10.1093/ndt/gfq631

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

Review 1.  Long-Term Outcomes in Patients with Acute Kidney Injury.

Authors:  Rebecca A Noble; Bethany J Lucas; Nicholas M Selby
Journal:  Clin J Am Soc Nephrol       Date:  2020-02-19       Impact factor: 8.237

2.  Effects of nicorandil on the reduction of BNP levels in patients with chronic kidney disease.

Authors:  Tomonori Kimura; Harumi Kitamura; Kazunori Inoue; Noritaka Kawada; Isao Matsui; Yasuyuki Nagasawa; Yoshitsugu Obi; Maki Shinzawa; Yasuhiko Sakata; Takayuki Hamono; Hiromi Rakugi; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2011-08-23       Impact factor: 2.801

3.  Impact of Acute Kidney Injury and Baseline Renal Impairment on Prognosis Among Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Ming-Yan Jiang
Journal:  Acta Cardiol Sin       Date:  2020-05       Impact factor: 2.672

Review 4.  Long-term prognosis after acute kidney injury (AKI): what is the role of baseline kidney function and recovery? A systematic review.

Authors:  Simon Sawhney; Mhairi Mitchell; Angharad Marks; Nick Fluck; Corrinda Black
Journal:  BMJ Open       Date:  2015-01-06       Impact factor: 2.692

5.  Chiral amino acid metabolomics for novel biomarker screening in the prognosis of chronic kidney disease.

Authors:  Tomonori Kimura; Kenji Hamase; Yurika Miyoshi; Ryohei Yamamoto; Keiko Yasuda; Masashi Mita; Hiromi Rakugi; Terumasa Hayashi; Yoshitaka Isaka
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379

6.  Identification of biomarkers for development of end-stage kidney disease in chronic kidney disease by metabolomic profiling.

Authors:  Tomonori Kimura; Keiko Yasuda; Ryohei Yamamoto; Tomoyoshi Soga; Hiromi Rakugi; Terumasa Hayashi; Yoshitaka Isaka
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.